RISA Labs

About RISA Labs

RISA Labs, founded in 2024 by IIT Kanpur graduates Kshitij Jaggi (CEO) and Kumar Shivang (CTO), is a Palo Alto-based health technology company developing an AI-driven operating system to automate and orchestrate complex healthcare workflows. The company's initial focus is on the oncology sector, addressing significant administrative bottlenecks that delay patient care. The founding team previously created the mental health platform Urban Health and leveraged their research experience, including work on 'Digital Twin Ecosystem in Oncology Clinical Operations', to inform the design of their current platform.

The company's core product is the Business Operating System as a Service (BOSS), an EHR-agnostic platform that acts as a full-stack orchestration engine. It connects directly to a healthcare provider's existing systems, such as electronic medical records (EMR), payer portals, and benefits systems. The platform uses a network of AI agents to manage time-consuming administrative tasks, including patient access, benefits verification, and prior authorizations. These AI agents can read, reason, and act across multiple systems to gather data, prepare submissions, track status, and adapt in real-time to changes in payer forms, rules, or interfaces. This automation aims to turn manual, unpredictable processes into high-throughput, predictable workflows.

RISA Labs provides the BOSS Console, a central control panel that allows institutions to configure and tailor workflows, routing, and practice-specific rules, ensuring the system functions as an extension of their own operations. Every action taken by the AI is designed to be traceable and auditable for compliance and clinical standards. The business model includes an upfront implementation fee, followed by charges for each process the software completes. The company serves cancer clinics, health systems, specialty pharmacies, and infusion networks across the United States. At one partner site, the platform reportedly freed up approximately 80% of administrative staff time, reduced denials by up to 40%, and achieved a 97.8% first-pass approval rate.

The company raised $3.5 million in a seed round in April 2025, led by Flipkart co-founder Binny Bansal. This was followed by an $11.1 million Series A round in January 2026, co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures, and others. These funds are intended to accelerate the deployment of its system across the US. RISA Labs plans to expand its AI-driven workflows across the continuum of cancer care, with specialty pharmacy operations identified as a near-term area for expansion.